iPS Cells
Health ministry panel conditionally approves iPS cell products
Von KI berichtet Bild generiert von KI
A health ministry expert panel has conditionally approved two regenerative medicine products derived from induced pluripotent stem (iPS) cells for treating Parkinson's disease and severe heart disease. This marks a potential world first in commercializing Nobel Prize-winning stem cell technology. The approval, based on small-scale clinical trials confirming safety and presumed efficacy, requires post-market verification within seven years.
Following an expert panel's recommendation last month, Japan's Health, Labor and Welfare Ministry on March 6 conditionally approved two iPS cell-derived regenerative medicines—the world's first commercialized such treatments—for severe heart failure and Parkinson's disease. The products carry conditions and time limits, with pricing and insurance coverage decisions next; sales could begin as early as summer 2026.